|
Heart failure
|
0.600 |
Biomarker
|
disease |
CTD_human |
Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data.
|
16777915 |
2006 |
|
Heart failure
|
0.600 |
Therapeutic
|
disease |
CTD_human |
Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data.
|
16777915 |
2006 |
|
Heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Echocardiography and the expression of BNP showed that rivaroxaban attenuated heart failure.
|
30867376 |
2019 |
|
Heart failure
|
0.600 |
Therapeutic
|
disease |
CTD_human |
Effects of combination of ACE inhibitor and angiotensin receptor blocker on cardiac remodeling, cardiac function, and survival in rat heart failure.
|
11136700 |
2001 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
CTD_human |
Effects of combination of ACE inhibitor and angiotensin receptor blocker on cardiac remodeling, cardiac function, and survival in rat heart failure.
|
11136700 |
2001 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Elevated circulating plasma NP levels correlate with the severity of heart failure and particularly BNP and the pro-peptide, NT-proBNP have been established as biomarkers for the diagnosis of heart failure as well as prognostic markers for cardiovascular risk.
|
29411335 |
2018 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Following the recommendation of natriuretic peptides (B-type natriuretic peptide and N-terminal-proBNP), many other biomarkers have been thoroughly studied to reflect different pathophysiological processes (such as fibrosis, inflammation, myocardial injury, and remodeling) in HF and some of them (like cardiac troponins, soluble suppression of tumorigenesis-2, and galectin 3) have subsequently been recommended to aid in the diagnosis and prognostication in HF.
|
31183637 |
2019 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
For example, GWAS of NT-proBNP levels not only identified variants in the NNPA-NPPB locus but also substantiated data suggesting that natriuretic peptides in itself are associated with a lower risk of hypertension and HF.
|
29912321 |
2018 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Functionally, knockdown of BRD4 greatly downregulated the NPPA and NPPB in vivo and in vitro, improved the hemodynamic and biometric parameters in rat with heart failure, as well as decreased the apoptosis occurrence.
|
29352508 |
2018 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
However, in multivariable regression analysis Cystatin C predicted mortality after the adjustment for baseline renal function, AKI, BNP levels and heart failure risk factors.
|
28756070 |
2017 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
However, the combination of miRNAs and BNP could increase the accuracy of detecting of heart failure.
|
28562533 |
2017 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
In BIO14.6 and BIO53.58 strains at this age, ventricular BNP and ANP gene expressions are augmented, and the plasma BNP concentration is elevated to 136 and 108 fmol/ml, respectively, three times greater than the elevated plasma ANP concentration, which well mimics changes of the plasma BNP and ANP concentrations in human heart failure.
|
8083346 |
1994 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
In the case of BNP-32, the sensor developed has a linear response from 1 pg mL<sup>-1</sup> to 1 μg mL<sup>-1</sup> in serum; for cTnI, linearity is observed from 1 pg mL<sup>-1</sup> to 10 ng mL<sup>-1</sup> as demanded for early-stage diagnosis of heart failure.
|
30320285 |
2018 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
RGD |
Increased plasma levels and blunted effects of brain natriuretic peptide in rats with congestive heart failure.
|
1831369 |
1991 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Natriuretic peptides (BNP and NT-proBNP) are largely used for monitoring patients with cardiac failure but are highly dependent on glomerular filtration rate (GFR).
|
30402040 |
2018 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
CTD_human |
Nesiritide: past, present, and future.
|
16333235 |
2005 |
|
Heart failure
|
0.600 |
Therapeutic
|
disease |
CTD_human |
Nesiritide: past, present, and future.
|
16333235 |
2005 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
NT -pro BNP as a Mediator of the Racial Difference in Incident Atrial Fibrillation and Heart Failure.
|
30912456 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
On multivariate analysis, admission initial stroke severity (OR 1.04, 95 CI% 1.004-1.07, p < 0.05) history of heart failure (OR 3.03, 95% CI 1.19-7.73, p < 0.05), ECG abnormalities and high BNP value (OR 4.34, 95% CI 2.59-7.29, p < 0.05) were associated with pure cardiac stroke mechanism.
|
29804788 |
2019 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Other cardiovascular complications seen in GBS patients were Increased pro-BNP(26.04%), raised troponin T levels(3.12%), acute coronary syndrome(2.08%), heart failure(2.08%) and abnormal 2D echo findings(8.33%).
|
31504947 |
2020 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Over time, FKBP12.6 over-expression reduced the molecular signature of left ventricular hypertrophy (LVH) and the transition to HF (BNP and β-MHC mRNAs) and attenuated Cn/NFAT activation in TAC-males only.
|
22007848 |
2011 |
|
Heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Patients with heart failure and CSA-CSR ± OSA have higher RRs but similar MV under ASV-therapy than patients with CSA and normal BNP.
|
29940592 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Progressive aortic constriction in growing pigs induces significant LV hypertrophy with cardiac fibrosis associated with left atrial dilation, raised filling pressures, and an ability to transition to overt HF with raised BNP without reduction in LVEF.
|
31851785 |
2020 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Receiver operating characteristic curve (ROC) analysis found that area under the ROC (AUC) was 0.616 (95%CI = 0.511-0.721, P = 0.034) when BNP was used to predict post-AMI HF, whereas AUC improved to 0.764 (95%CI = 0.674-0.855, P < 0.001) when miR-150 was used.
|
30745540 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Receiver operating curves (ROC) were obtained to identify the best cut-off of BNP, global longitudinal strain (GLS), E/E' and left atrial volume index (LAVI) for the identification of patients with HFpEF whenever compared with those without heart failure.We analyze data from 195 age-matched and sex-matched patients: 65 patients with heart failure with reduced ejection fraction, 65 patients with HFpEF and 65 stroke patients.
|
29553992 |
2018 |